STOCK TITAN

Tiziana Life Sciences to Present at the 37th Annual Roth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences

Tiziana Life Sciences (Nasdaq: TLSA), a biotechnology company focused on developing breakthrough immunomodulation therapies, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.

CEO Ivor Elrifi will lead a virtual fireside chat on Tuesday, March 18, 2025, at 12:00 pm PST (15:00 ET / 19:00 GMT). The company will also participate in one-on-one investor meetings during the conference.

The event will feature approximately 450 private and public companies from various growth sectors, offering opportunities for 1-on-1 meetings, analyst-selected fireside chats, and industry keynotes. Tiziana's lead development candidate is intranasal foralumab, a fully human, anti-CD3 monoclonal antibody.

Tiziana Life Sciences (Nasdaq: TLSA), un'azienda biotecnologica focalizzata sullo sviluppo di terapie innovative per l'immunomodulazione, ha annunciato la sua partecipazione al 37° Annual ROTH Conference che si svolgerà dal 16 al 18 marzo 2025 a Dana Point, California.

Il CEO Ivor Elrifi condurrà una chiacchierata virtuale il martedì 18 marzo 2025 alle 12:00 PST (15:00 ET / 19:00 GMT). L'azienda parteciperà anche a incontri individuali con gli investitori durante la conferenza.

L'evento presenterà circa 450 aziende private e pubbliche provenienti da vari settori in crescita, offrendo opportunità per incontri 1-a-1, chiacchierate selezionate dagli analisti e keynote di settore. Il principale candidato allo sviluppo di Tiziana è il foralumab intranasale, un anticorpo monoclonale anti-CD3 completamente umano.

Tiziana Life Sciences (Nasdaq: TLSA), una empresa biotecnológica centrada en el desarrollo de terapias innovadoras de inmunomodulación, ha anunciado su participación en la 37ª Conferencia Anual ROTH que se llevará a cabo del 16 al 18 de marzo de 2025 en Dana Point, California.

El CEO Ivor Elrifi liderará una charla virtual el martes 18 de marzo de 2025 a las 12:00 pm PST (15:00 ET / 19:00 GMT). La empresa también participará en reuniones individuales con inversionistas durante la conferencia.

El evento contará con aproximadamente 450 empresas privadas y públicas de varios sectores en crecimiento, ofreciendo oportunidades para reuniones 1-a-1, charlas seleccionadas por analistas y discursos principales de la industria. El principal candidato en desarrollo de Tiziana es foralumab intranasal, un anticuerpo monoclonal anti-CD3 completamente humano.

Tiziana Life Sciences (Nasdaq: TLSA)는 혁신적인 면역 조절 치료법 개발에 집중하는 생명공학 회사로, 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트에서 열리는 제37회 연례 ROTH 컨퍼런스에 참여한다고 발표했습니다.

CEO 이보르 엘리피는 2025년 3월 18일 화요일 오후 12시 PST (동부 표준시 15:00 / GMT 19:00)에 가상 대담을 이끌 예정입니다. 회사는 컨퍼런스 동안 투자자와의 일대일 미팅에도 참여할 것입니다.

이 행사에는 다양한 성장 분야에서 약 450개의 민간 및 공공 기업이 참여하여 1대1 미팅, 분석가가 선택한 대담, 산업 기조 연설의 기회를 제공합니다. Tiziana의 주요 개발 후보는 완전 인간형 anti-CD3 단클론 항체인 비강 투여용 포랄루맙입니다.

Tiziana Life Sciences (Nasdaq: TLSA), une entreprise de biotechnologie axée sur le développement de thérapies innovantes en immunomodulation, a annoncé sa participation à la 37ème Conférence Annuelle ROTH qui se tiendra du 16 au 18 mars 2025 à Dana Point, Californie.

Le PDG Ivor Elrifi animera une discussion virtuelle le mardi 18 mars 2025 à 12h00 PST (15h00 ET / 19h00 GMT). L'entreprise participera également à des réunions individuelles avec des investisseurs pendant la conférence.

L'événement réunira environ 450 entreprises privées et publiques de divers secteurs en croissance, offrant des opportunités de réunions en tête-à-tête, de discussions sélectionnées par des analystes et de discours d'experts du secteur. Le principal candidat au développement de Tiziana est le foralumab intranasal, un anticorps monoclonal anti-CD3 entièrement humain.

Tiziana Life Sciences (Nasdaq: TLSA), ein Biotechnologieunternehmen, das sich auf die Entwicklung bahnbrechender Immunmodulationstherapien konzentriert, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz angekündigt, die vom 16. bis 18. März 2025 in Dana Point, Kalifornien, stattfindet.

CEO Ivor Elrifi wird am Dienstag, den 18. März 2025 um 12:00 Uhr PST (15:00 Uhr ET / 19:00 Uhr GMT) eine virtuelle Gesprächsrunde leiten. Das Unternehmen wird auch an individuellen Investorenmeetings während der Konferenz teilnehmen.

Die Veranstaltung wird etwa 450 private und öffentliche Unternehmen aus verschiedenen Wachstumssektoren umfassen und bietet Möglichkeiten für 1-zu-1-Meetings, von Analysten ausgewählte Gesprächsrunden und Branchen-Keynotes. Tizianas Hauptentwicklungskandidat ist intranasales Foralumab, ein vollständig menschlicher anti-CD3-monoklonaler Antikörper.

Positive
  • None.
Negative
  • None.

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that the CEO of Tiziana Life Sciences, Ivor Elrifi, will be presenting during a fireside chat at the 37th Annual ROTH Conference and host 1x1 investor meetings. The Conference is being held March 16-18, 2025, in Dana Point, California. This year’s event will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors.

Presentation Details:
Date: Tuesday, March 18, 2025
Time of Presentation: 12:00 pm PST / 15:00 pm ET / 19:00 pm GMT
Format: Virtual Fireside Chat
1x1 Meetings: Please contact your ROTH representative.

You can register online to view the webcast here: Link

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. The FDA has allowed an additional 20 patients to be enrolled in this EA program. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development, binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been observed in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

[1] https://www.pnas.org/doi/10.1073/pnas.2220272120

[2] https://www.pnas.org/doi/10.1073/pnas.2309221120


FAQ

When is Tiziana Life Sciences (TLSA) presenting at the 2025 ROTH Conference?

Tiziana Life Sciences will present on Tuesday, March 18, 2025, at 12:00 pm PST (15:00 ET / 19:00 GMT) through a virtual fireside chat.

What is Tiziana Life Sciences' (TLSA) main development product discussed at ROTH 2025?

Tiziana's lead development candidate is intranasal foralumab, a fully human, anti-CD3 monoclonal antibody for immunomodulation therapy.

How can investors meet with Tiziana Life Sciences (TLSA) at the ROTH Conference 2025?

Investors can arrange 1-on-1 meetings with Tiziana Life Sciences by contacting their ROTH representative.

What type of companies are participating in the 2025 ROTH Conference alongside TLSA?

Approximately 450 private and public companies from various growth sectors are participating in the conference.
Tiziana Life Sciences Ltd Com

NASDAQ:TLSA

TLSA Rankings

TLSA Latest News

TLSA Stock Data

112.93M
71.31M
35.56%
0.89%
0.55%
Biotechnology
Healthcare
Link
United Kingdom
London